Citius Oncology Inc. (CTOR)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Citius Oncology Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 9.19M | $13.57M | $6.32M | -$7.25M | -53.46% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 1 | $0.62 | $0.65 | $0.03 | 4.84% |
Citius Oncology Inc. (CTOR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Citius Oncology Inc. ever had a stock split?
Citius Oncology Inc. Profile
| Biotechnology Industry | Healthcare Sector | Leonard L. Mazur CEO | NASDAQ (CM) Exchange | 17331Y109 CUSIP |
| US Country | 285 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Citius Oncology, Inc. is a pioneering biopharmaceutical company dedicated to the advancement of innovative cancer therapies. With its headquarters based in the vibrant city of New York, New York, the company stands out for its commitment to addressing the most pressing needs in the field of oncology. Operating under the umbrella of Citius Pharmaceuticals, Inc., Citius Oncology, Inc. leverages a wealth of scientific expertise and resources to bring novel treatments to patients who face dire prognoses. The company's strategic focus on targeted oncology therapies is a testament to its forward-thinking approach to drug development and its unwavering commitment to improving patient outcomes in the battle against cancer.
Products and Services
- Development of Novel Targeted Oncology Therapies
Citius Oncology, Inc. is at the forefront of creating innovative treatments specifically designed to target cancer cells, sparing healthy tissues and minimizing side effects. These targeted therapies represent a new wave of cancer treatment, offering hope for improved efficacy and patient quality of life.
- LYMPHIR Development for Cutaneous T-Cell Lymphoma
LYMPHIR is Citius Oncology's leading investigational drug, representing a significant stride in the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma, a rare and challenging type of cancer. This orphan indication underscores the company's commitment to addressing unmet medical needs within the oncology space, where options for patients may be limited or non-existent.
